Maravai LifeSciences Holdings, Inc. reports recurring developments as a life sciences supplier of reagents and services for drug therapy, diagnostics, vaccine and human disease research. Company updates center on its TriLink nucleic acid synthesis business, including mRNA, oligonucleotides and CleanCap-related technologies, and its Cygnus biologics safety testing business, including host cell protein ELISA kits, impurity detection assays, reagents and services.
News about MRVI commonly covers quarterly financial results, segment revenue trends, guidance, restructuring and operating cost initiatives, investor conference participation, executive and board changes, and product or commercial updates tied to researchers, biotech innovators, vaccine developers, diagnostics companies and cell and gene therapy customers.
Maravai LifeSciences (NASDAQ: MRVI) will participate in two upcoming investor conferences in September 2022. CEO Carl Hull will engage in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 12 at 9:20 a.m. ET, followed by a presentation at the Baird Global Healthcare Conference on September 13 at 9:05 a.m. ET. Live webcasts of these events will be available on Maravai's Investor Relations website, with archived versions accessible post-event. Maravai specializes in providing life science reagents and services for drug development, diagnostics, and research.
Summary not available.
Maravai LifeSciences Holdings (MRVI) reported record financial results for Q2 2022, with revenue of $242.7 million, an 11% increase year-over-year. The Nucleic Acid Production segment saw a 17% revenue increase to $225.2 million. Net income reached $156.7 million, up 17% from the previous year. Noteworthy is the 42% growth in Nucleic Acid Production for the first half of 2022. The company signed a Cooperative Agreement with the Department of Defense for manufacturing expansion. Adjusted EBITDA for Q2 was $188.5 million, reflecting strong cash position for future growth.
Maravai LifeSciences (MRVI) will release its second quarter 2022 financial results post-market on August 4, 2022. A conference call will follow at 2:00 p.m. PT/5:00 p.m. ET, accessible via phone or webcast. The company specializes in life science products critical for drug therapy and vaccine development, supporting biotechnology and pharmaceutical sectors globally.
TriLink BioTechnologies, a subsidiary of Maravai LifeSciences (NASDAQ: MRVI), has appointed Dr. Kate Broderick as Senior Vice President of Research and Development. In this role, she will spearhead the company's R&D strategy and contribute to its growth as a key supplier of modified nucleic acids. Dr. Broderick brings over 15 years of experience from Inovio Pharmaceuticals, along with expertise in DNA technology, gene delivery, and vaccine development. Her leadership is expected to bolster TriLink's capabilities in supporting clients through clinical trials and product development.
Maravai LifeSciences (NASDAQ: MRVI) announced the appointment of Dr. Peter Leddy as Executive Vice President and Chief Administrative Officer. Dr. Leddy will lead global shared services functions, including Human Resources, Environmental, Social and Governance initiatives, and Diversity, Equity and Inclusion efforts. With over 30 years in the healthcare sector, his experience aims to foster long-term growth and enhance company culture. He previously consulted for Maravai and has held executive roles in various organizations. This strategic hire is expected to strengthen leadership as Maravai evolves in its market.
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), announced a Cooperative Agreement with the Army Contracting Command to enhance its domestic production capacity for crucial mRNA vaccine components. The Department of Defense will fund up to $39 million for the expansion in San Diego, California, aimed at increasing manufacturing of nucleoside triphosphates and CleanCap® capping reagents. This initiative will also prepare the U.S. for future pandemics, addressing heightened demand for nucleic acid products critical to COVID-19 vaccine development.
Maravai LifeSciences (NASDAQ: MRVI) is set to participate in several upcoming investor conferences. CFO Kevin Herde will engage in a fireside chat at the UBS Global Healthcare Conference on May 25, 2022, followed by a presentation at the William Blair Growth Conference on June 8, 2022. Additionally, Mr. Herde will participate in another fireside chat at the Goldman Sachs Global Healthcare Conference on June 14, 2022. Webcasts of these events will be available on the Maravai Investor Relations website, along with archived versions post-event.
Maravai LifeSciences Holdings reported strong financial results for Q1 2022, with record revenues of $244.3 million, a 65% year-over-year increase. The Nucleic Acid Production segment grew 80.5%, driven by a high demand for COVID-19 related CleanCap products. The company achieved a net income of $146.9 million, up 95% from the previous year, alongside an Adjusted EBITDA of $187 million. Maravai has raised its guidance for Adjusted EBITDA and Adjusted EPS for the full year 2022, reflecting optimism in ongoing therapeutic and vaccine developments beyond COVID-19.
Maravai LifeSciences, Inc. (NASDAQ: MRVI) will report its first quarter 2022 financial results on May 5, 2022, post-market. A conference call is scheduled for the same day at 2:00 PM PT. Investors can participate by calling (800) 806-5484 or (416) 340-2217, using the passcode 7725912#. A replay will be available for 72 hours at (800) 408-3053 or (905) 694-9451, along with a webcast on the Maravai website.
Maravai specializes in life science reagents and services, supporting drug therapies, diagnostics, and vaccine development for leading global biopharmaceutical companies.